

Transgenomic to Present at the Oppenheimer 22nd Annual Healthcare Conference

Omaha, Neb. (December 7, 2011) – Transgenomic, Inc. (OTC/BB: TBIO) today announced that Craig Tuttle, Chief Executive Officer of Transgenomic, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 2:25 PM Eastern Time at The Waldorf=Astoria Hotel in New York City.

About Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.